Anthony S. Fauci, MD, was chief of the Laboratory of Immunoregulation at the National Institute of Allergy and Infectious Disease (NIAID) when he read about a strange form of pneumonia that had killed more than two dozen young, otherwise healthy gay men in Los Angeles in the span of a month. Continued

An HIV vaccine candidate developed at the Duke Human Vaccine Institute triggered low levels of an elusive type of broadly neutralizing HIV antibodies among a small group of people enrolled in a 2019 clinical trial.

DURHAM, N.C. – A team led by the Duke Human Vaccine Institute (DHVI) has developed a vaccine approach that works like a GPS, guiding the immune system through the specific steps to make broadly neutralizing antibodies against HIV.

The Duke Human Vaccine Institute has received a federal contract to manufacture a pan-coronavirus vaccine candidate that can be tested in a phase 1 clinical trial.   Awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), the base period of the contract provides $11.2 million to support the program; additional provisions in the contract could increase the total funding up to $21.5 million if all option periods are exercised.

Researchers at the Duke Human Vaccine Institute (DHVI) received a federal grant totaling more than $27 million over five years to focus on building structural models of HIV that will help guide the development of therapies and vaccines.